JP2018531886A5 - - Google Patents

Download PDF

Info

Publication number
JP2018531886A5
JP2018531886A5 JP2018506211A JP2018506211A JP2018531886A5 JP 2018531886 A5 JP2018531886 A5 JP 2018531886A5 JP 2018506211 A JP2018506211 A JP 2018506211A JP 2018506211 A JP2018506211 A JP 2018506211A JP 2018531886 A5 JP2018531886 A5 JP 2018531886A5
Authority
JP
Japan
Prior art keywords
composition
disease
individual
disorder
caulobacter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018506211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531886A (ja
JP7223989B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/055016 external-priority patent/WO2017033123A1/en
Publication of JP2018531886A publication Critical patent/JP2018531886A/ja
Publication of JP2018531886A5 publication Critical patent/JP2018531886A5/ja
Application granted granted Critical
Publication of JP7223989B2 publication Critical patent/JP7223989B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018506211A 2015-08-25 2016-08-22 免疫調節組成物およびその使用方法 Active JP7223989B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562209693P 2015-08-25 2015-08-25
PCT/IB2016/055016 WO2017033123A1 (en) 2015-08-25 2016-08-22 Immunomodulatory compositions and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2018531886A JP2018531886A (ja) 2018-11-01
JP2018531886A5 true JP2018531886A5 (https=) 2019-09-26
JP7223989B2 JP7223989B2 (ja) 2023-02-17

Family

ID=58100011

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018506211A Active JP7223989B2 (ja) 2015-08-25 2016-08-22 免疫調節組成物およびその使用方法

Country Status (7)

Country Link
US (3) US11065283B2 (https=)
EP (2) EP4480544A3 (https=)
JP (1) JP7223989B2 (https=)
CN (1) CN107921113A (https=)
AU (2) AU2016311387B2 (https=)
HK (1) HK1248531A1 (https=)
WO (1) WO2017033123A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11213570B2 (en) * 2016-06-10 2022-01-04 The Johns Hopkins University Use of C1q/TNF-related protein-1 (CTRP1) to treat fatty liver disease
CN108888762A (zh) * 2018-08-15 2018-11-27 福建傲农生物科技集团股份有限公司 一种含益生菌代谢产物的组合物
US20250009815A1 (en) * 2019-02-12 2025-01-09 Sanzyme Biologics Private Limited Composition for competitive inhibition of pathogens and restoration of microbial ecological balance
CN109966320B (zh) * 2019-04-26 2022-08-05 青岛东海药业有限公司 凝结芽孢杆菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用
US20220218818A1 (en) * 2019-06-03 2022-07-14 Immunolux International Corp. Smallpox vaccine and stem cells for treatment of disease
KR102149102B1 (ko) * 2019-07-05 2020-08-27 에스케이바이오랜드 주식회사 피부보습 및 피부재생 기능이 있는 더모바이오틱스 블록 조성물의 제조방법
EP3838269A1 (en) * 2019-12-16 2021-06-23 European Molecular Biology Laboratory Compounds and pharmaceutical compositions for prevention and/or treatment of dysbiosis and antibacterial antidotes for microbiome-protection
CN113440609A (zh) * 2020-03-27 2021-09-28 北京市农林科学院 一种双链rna复合物autp及其在疫苗制备中的应用
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN113198004B (zh) * 2021-05-19 2022-08-19 天津市宝恒生物科技有限公司 一种修复肠粘膜的凝结芽孢杆菌制剂
CN113975278B (zh) * 2021-10-29 2023-04-07 中国科学院昆明动物研究所 溴隐亭在制备治疗非洲猪瘟的产品中的应用
US20250230230A1 (en) * 2022-03-24 2025-07-17 The Brigham And Women's Hospital, Inc. Treatment of perivascular fibrosis and other hypertensive diseases and conditions
TW202440070A (zh) * 2023-03-15 2024-10-16 澳大利亞商拓比利亞澳洲有限公司 用於治療、改善或預防病毒感染的製品及治療組合以及其製備及使用方法
CN117357777A (zh) * 2023-10-30 2024-01-09 重庆国际免疫创新中心有限公司 一种用于治疗多发性硬化症的微针贴及其应用
US12268717B1 (en) 2024-03-01 2025-04-08 Malireddy S. Reddy Enhanced microbial therapeutic agents
WO2025226956A1 (en) * 2024-04-26 2025-10-30 The Board Of Trustees Of The University Of Illinois Catechol o-methyltransferase inhibitors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5736371A (en) 1991-06-04 1998-04-07 A Et S Biovecteurs Biodegradable particulate vector for transporting molecules having biological activity
DE69230613T2 (de) 1991-07-02 2000-12-28 Inhale Inc Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform
US5711968A (en) 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
JP3220331B2 (ja) 1993-07-20 2001-10-22 エチコン・インコーポレーテツド 非経口投与用の吸収性液体コポリマー類
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
EP0842657A1 (en) 1996-11-19 1998-05-20 OctoPlus B.V. Microspheres for controlled release and processes to prepare these microspheres
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
EP1003850B1 (en) 1997-06-06 2009-05-27 The Regents of the University of California Inhibitors of dna immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GEP20022707B (en) 1997-07-18 2002-06-25 Infimed Inc Us Biodegrading Macromers for the Controlled Release of Biologically Active Substances
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
JP4549529B2 (ja) 1998-01-30 2010-09-22 サイオス，インコーポレーテッド ペプチドまたはタンパク質の制御放出送達
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
JP2002537351A (ja) * 1999-02-22 2002-11-05 ユニバーシティ・オブ・ブリティッシュ・コロンビア コーロバクターリポ多糖免疫アジュバント
ATE459373T1 (de) 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
HUP0202885A3 (en) 1999-09-24 2004-07-28 Smithkline Beecham Biolog Vaccines
US6458398B1 (en) 1999-10-18 2002-10-01 Eco Pure Food Safety Systems, Inc. Cold water disinfection of foods
BR0107942A (pt) 2000-01-28 2004-01-06 Infimed Therapeutics Inc Polìmeros de proteìna de liberação lenta
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
JP2004533421A (ja) 2001-03-27 2004-11-04 バイオミラ，インコーポレイテッド Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
CA2935511C (en) 2014-01-07 2023-04-04 Babita Agrawal Immunomodulatory compositions comprising heat-killed caulobacter crescentus and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2018531886A5 (https=)
Lee et al. Pectic polysaccharides: Targeting gut microbiota in obesity and intestinal health
JP2014534957A5 (https=)
JP2019031541A5 (https=)
JP2017531002A5 (https=)
JP2010535215A5 (https=)
JP2009528991A5 (https=)
JP2010535218A5 (https=)
JP2009531292A5 (https=)
HRP20211050T1 (hr) Pripravci i postupci liječenja degradacije mrežnice
JP2018203742A5 (https=)
HRP20160843T1 (hr) Bakterija za upotrebu kao probiotik za nutritivne i medicinske primjene
RU2008137086A (ru) Борсодержащие малые молекулы в качестве противовоспалительных средств
Kowalewicz-Kulbat et al. BCG for the prevention and treatment of allergic asthma
JP2022506898A5 (https=)
Nuckols et al. Effects of a soft robotic glove using a high repetition protocol in chronic stroke: A pilot study
EP2706067A1 (en) Probiotic bacteria as carrier for a helminth-derived immunomodulator for the treatment of inflammatory disorders
Guo et al. Engineered probiotics introduced to improve intestinal microecology for the treatment of chronic diseases: present state and perspectives
JP2019531352A5 (https=)
HRP20200001T1 (hr) Kristalični oblik spoja (s)-3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-propan-1,2-diol
Giri et al. Probiotics and prebiotics in the suppression of autoimmune diseases
Rovenský et al. Treatment of adjuvant-induced arthritis with the combination of methotrexate and probiotic bacteria Escherichia coli O83 (Colinfant®)
Paz et al. Postbiotics and atopic dermatitis: Aiming to modulate the gut-skin axis
MX2024001868A (es) Ligandos analogos de tetrahidropirazolopiridina de nlrx1 y usos de los mismos.
Esposito et al. Immunomodulation for recurrent respiratory tract infections: new insights and perspectives